India’s Supreme Court Dismisses Novartis’ Glivec Patent; Upholds Section 3(d) Of India Patent Act
This article was originally published in PharmAsia News
Executive Summary
The top court delivered a landmark judgment that threatens to deter future Big Pharma investments in India.